Navigating the rapidly changing oncology treatment landscape: how digital tools can help
May 2, 2024 | Access, clinical trials, digital health, digital tools, oncology, patient insight-gathering, reimbursement
With rapid growth comes growing pains…
The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). However, with rapid growth comes growing pains.
Specific challenges facing the oncology field
1. Increased competition and evolving standard of care
New competitors are entering the market at a rapid pace, and competition is intensifying. There are currently more than 2,000 oncology products under development. Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017). This competitive intensity tends to focus on smaller patient populations with multiple treatment options.
With a larger number of treatable patients, improving survival rates, more clinical trials, and increased focus on real-world evidence, the definition of ‘standard of care’ is continuously changing. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers.
Further, the time advantage traditionally afforded to new cancer therapies has been substantially reduced due to advances in our understanding of the underlying tumor biology and the emergence of novel treatment modalities. Occasionally, the advantage disappears well before the period of exclusivity ends (2)…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Leadership Lessons Learned from the Pandemic
Alok Kanti, President & CEO of Bayer Canada, discusses a variety of topics, including his experience with leading an entire organization through the COVID-19 pandemic and where he sees digital health…
Overcoming Behavioral Health Access Limitations Through Telemedicine
Phil Hirsh, PhD, Founder & Chief Executive at Synergia Integrated teleBehavioral Health; and Craig Wright, MD, Senior Physician Executive and Consultant, discuss a range of topics surrounding telemedicine and other digital health…
Commercial Execution Strategies During & After the Pandemic
Frank Armenante, Director of Commercial Execution at Novo Nordisk, discusses a range of topics, from the impact of COVID-19 on commercial operations and the digitization of Pharma to his leadership lessons…
Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal
Even after the pandemic is long behind us, virtual collaboration will become mainstay in Pharma.
Pharma, Technology, and Healthcare in the New Normal
Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses a range of hot topics, from Brian’s leadership lessons and tips to the impact of the COVID-19 pandemic on the way that Pharma…
Solving the Caregiver Crisis Through Technology
Curtis Khan, CEO and Founder of BookJane, discusses the ongoing caregiver crisis and how BookJane’s solutions and other digital technologies can help to close this gap. We also delve into how…
Therapeutic VR for Managing Pain & Improving Patient Outcomes
Ramsay Brown, CEO and Founder of Quol, delves into several different HealthTech topics, including the concept of VR therapeutics and the importance of incorporating behavioral science and neuroscience into VR solutions, as…
Visual Storytelling in HealthTech
Rodney Hu, founder of 209|Digital and a popular podcast host. We explore Rodney’s work within the HealthTech space and what he believes has to happen for the healthcare industry to more…
Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
Sandra Graham-Mason, Director of Marketing at Regeneron Pharmaceuticals discusses a variety of topics, from the impact of COVID-19 on the way that Pharma teams interact with internal stakeholders and KOLs to…
Roles of Neuroscience & AI in Solving Complex Healthcare Challenges
Dr. Phillip Alvelda, CEO and Co-Founder of Brainworks, discusses all things artificial intelligence and machine learning. We also explore the concepts of whole-brain AI systems and ambient biometrics, and how AI-enhanced vital…